RBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $1215
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Regeneron Pharmaceuticals but lowers the price target from $1260 to $1215.
November 01, 2024 | 5:51 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital maintains an Outperform rating on Regeneron Pharmaceuticals but reduces the price target from $1260 to $1215, indicating a slightly less optimistic outlook.
The Outperform rating suggests continued confidence in Regeneron's performance, but the lowered price target indicates a tempered outlook. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100